Saved in:
| Main Author: | |
|---|---|
| Format: | Artículo científico |
| Language: | en |
| Published: |
Sociedad Española de Farmacia Hospitalaria
2009
|
| Subjects: | |
| Online Access: | https://www.redalyc.org/articulo.oa?id=365961789006 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Table of Contents:
- Effectiveness and safety of erlotinib in 2 patients with carcinoma of the cervix I. Pérez Rodrigo R. Albornoz López M. Soto Rojas I. Fernández García V. Torres Degayón Medicina use Safety Erlotinib Compassionate Effectiveness Objective: To assess the effectiveness and safety of the use of erlotinib in the treatment of refractory cervical cancer after retrospective analysis of 2 clinical cases.Methods: The clinical records were assessed for the patients who started treatment with erlotinib, on a compassionate-use basis, with an oral dosage of 150mg/day until June 2008. The pharmacy dispensing records were also assessed to evaluate adherence to treatment. Progression-free survival was assessed and adverse reactions were recorded in the medical records.Results: Three patients with recurrent, advanced cervical cancer were candidates for treatment with erlotinib, 2 of whom were only starting treatment. In both cases, the women had previously received between 3 and 4 different treatment lines. Progression-free survival was 6 months and 4 months in each case. The adverse reactions to the treatment were slight.Conclusions: Erlotinib presented some similar results to those obtained from cisplatin doublets in women with refractory cervical cancer, with minor adverse effects. However, these results need to be corroborated in the clinical studies field on a wider section of the population. 2009 artículo científico 1130-6343 https://www.redalyc.org/articulo.oa?id=365961789006 en http://www.redalyc.org/revista.oa?id=3659 Farmacia Hospitalaria application/pdf Sociedad Española de Farmacia Hospitalaria Farmacia Hospitalaria (España) Num.2 Vol.33